Report cover image

Cystic Fibrosis Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Publisher Fortune Business Insights Pvt. Ltd.
Published Dec 01, 2024
Length 120 Pages
SKU # FOB19410797

Description

Cystic Fibrosis Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032



Growth Factors of Cystic Fibrosis Market

The cystic fibrosis market size was valued at USD 5.12 billion in 2019, and the market is now projected to grow from USD 62.57 billion by 2032, exhibiting a CAGR of 20.1% during the forecast period of 2020-2027.

The COVID-19 pandemic affects cystic fibrosis (CF) disease because patients with CF are vulnerable to the development of various lung-associated problems and diabetes due to the disease. The virus directly impacts the cystic fibrosis market growth. The ECFS, one of the organizations concerned is closely evaluating the data gathered from the Patient Registry to determine the actual effect of COVID-19 on people with CF. Strategies to promote data sharing with National CF registries seek to find out factors that would determine the worsening of the disease. This improves CF patient management and treatment through this data analysis approach.

The cystic fibrosis market share is attributed to the rising rate of occurrence of the genetic disorder-cystic fibrosis that affects more than 70,000 people around the globe. Around 1000 new cases annually are identified, implying the need for respiratory, gastrointestinal and reproductive treatment approaches. Developments in diagnostic capabilities permit early identification, boosting the availability of appropriate cures. This trend is favourable for the improvement of the conditions for patients and helps the market to strengthen. The increase in the number of patients with CF is the rationale for the steady advancement in treating the disease.

Further, the increasing number of cystic fibrosis (CF) cases contributes to improving the treatment sector's pharmacotherapy direction and the positive trends of the market. Large firms are paying concentration to pipeline candidates that aim at the CFTR protein defects. The new drugs such as Ivacaftor/Lumacaftor have eased the care provision greatly as the patient prognosis improves. Advances in research and development and technology are spurring new product development in the form of product innovations. These are some of the advancements opening up the market and the status of those diagnosed with cystic fibrosis.

Comprehensive Analysis of Cystic Fibrosis Market

The cystic fibrosis market and healthcare industry is rising at an exponential rate due to its market segmentation. This market expansion effectively provides a detailed regional assessments considering the dominant supply and demand forces that impact the pharmacy benefit management industry. These segmentations are methodically segregated by drug class, by route of administration and by distribution channel. The drug class includes Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), Bronchodilators, Mucolytic, Pancreatic Enzyme Supplement and Others. The route of administration includes, Oral and Parenteral. The distribution channel includes, Retail Pharmacies & Drug Stores, Online Pharmacies and Hospital Pharmacies.

North America was the largest CAGR in the cystic fibrosis market valued at USD 3.89 billion in 2019. They also provided data suggesting North America should remain the global market leader. The factors responsible for strengthening the market in certain regions are an increase in cases of CF, several patients suffering from various respiratory diseases affecting CF, enhancement in research and development activities, a rise in healthcare expenditures and so on.

The top market players play a crucial role in the healthcare industry, assuring industrial prospectus growth and setting market standards. These players include Vertex Pharmaceuticals Incorporated, AbbVie Inc., Novartis AG, Gilead Sciences, Inc., Mylan N.V., Pfizer Inc., Bayer AG, Genentech, Inc., AstraZeneca and others. These market players provide a level-playing competitive landscape.

In October 2019, AbbVie Inc. revealed its partnership with the Cystic Fibrosis Foundation to advance the CFTR potentiator compound obtained from the foundation.

Segmentation Table

Global Cystic Fibrosis Market Scope

Study Period2019-2027

Base Year2019

Forecast Period2020-2027

Growth RateCAGR of 20.1% from 2020 to 2027

Historical Period2016-2018

UnitValue (USD Billion)

SegmentationBy Drug Class, Route of Administration, Distribution Channel, and Region

By Drug ClassCystic Fibrosis Transmembrane Conductance Regulator (CFTR)

Bronchodilators

Mucolytic

Pancreatic Enzyme Supplement

Others

By Route of AdministrationOral

Parenteral

By Distribution ChannelRetail Pharmacies & Drug Stores

Online Pharmacies

Hospital Pharmacies

By RegionNorth America (U.S. and Canada)

Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)

Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia- Pacific)

Rest of the World


Please Note: It will take 5-6 business days to complete the report upon order confirmation.

Table of Contents

120 Pages
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4. Key Insights
4.1. New Product Launches
4.2. Prevalence of Cystic Fibrosis
4.3. Pipeline Analysis
4.4. Key Industry Developments (Mergers, Acquisitions, and Partnerships, etc.)
5. Global Cystic Fibrosis Market Analysis, Insights and Forecast, 2016-2027
5.1. Key Findings / Summary
5.2. Market Analysis, Insights and Forecast – By Drug Class
5.2.1. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
5.2.2. Bronchodilators
5.2.3. Mucolytic
5.2.4. Pancreatic Enzyme Supplement
5.2.5. Others
5.3. Market Analysis, Insights and Forecast – By Route of Administration
5.3.1. Oral
5.3.2. Parenteral
5.4. Market Analysis, Insights and Forecast – By Distribution Channel
5.4.1. Hospital Pharmacies
5.4.2. Retail Pharmacies & Drug Stores
5.4.3. Online Pharmacies
5.5. Market Analysis, Insights and Forecast – By Region
5.5.1. North America
5.5.2. Europe
5.5.3. Asia pacific
5.5.4. Rest of the World
6. North America Cystic Fibrosis Market Analysis, Insights and Forecast, 2016-2027
6.1. Key Findings / Summary
6.2. Market Analysis – By Drug Class
6.2.1. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
6.2.2. Bronchodilators
6.2.3. Mucolytic
6.2.4. Pancreatic Enzyme Supplement
6.2.5. Others
6.3. Market Analysis – By Route of Administration
6.3.1. Oral
6.3.2. Parenteral
6.4. Market Analysis – By Distribution Channel
6.4.1. Hospital Pharmacies
6.4.2. Retail Pharmacies & Drug Stores
6.4.3. Online Pharmacies
6.5. Market Analysis – By Country
6.5.1. U.S.
6.5.2. Canada
7. Europe Cystic Fibrosis Market Analysis, Insights and Forecast, 2016-2027
7.1. Key Findings / Summary
7.2. Market Analysis – By Drug Class
7.2.1. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
7.2.2. Bronchodilators
7.2.3. Mucolytic
7.2.4. Pancreatic Enzyme Supplement
7.2.5. Others
7.3. Market Analysis – By Route of Administration
7.3.1. Oral
7.3.2. Parenteral
7.4. Market Analysis – By Distribution Channel
7.4.1. Hospital Pharmacies
7.4.2. Retail Pharmacies & Drug Stores
7.4.3. Online Pharmacies
7.5. Market Analysis – By Country/ sub-region
7.5.1. U.K.
7.5.2. Germany
7.5.3. France
7.5.4. Spain
7.5.5. Italy
7.5.6. Scandinavia
7.5.7. Rest of Europe
8. Asia pacific Cystic Fibrosis Market Analysis, Insights and Forecast, 2016-2027
8.1. Key Findings / Summary
8.2. Market Analysis – By Drug Class
8.2.1. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
8.2.2. Bronchodilators
8.2.3. Mucolytic
8.2.4. Pancreatic Enzyme Supplement
8.2.5. Others
8.3. Market Analysis – By Route of Administration
8.3.1. Oral
8.3.2. Parenteral
8.4. Market Analysis – By Distribution Channel
8.4.1. Hospital Pharmacies
8.4.2. Retail Pharmacies & Drug Stores
8.4.3. Online Pharmacies
8.5. Market Analysis – By Country/ sub-region
8.5.1. Japan
8.5.2. China
8.5.3. India
8.5.4. Australia
8.5.5. Southeast Asia
8.5.6. Rest of Asia Pacific
9. Rest of the World Cystic Fibrosis Market Analysis, Insights and Forecast, 2016-2027
9.1. Key Findings / Summary
9.2. Market Analysis – By Drug Class
9.2.1. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
9.2.2. Bronchodilators
9.2.3. Mucolytic
9.2.4. Pancreatic Enzyme Supplement
9.2.5. Others
9.3. Market Analysis – By Route of Administration
9.3.1. Oral
9.3.2. Parenteral
9.4. Market Analysis – By Distribution Channel
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies & Drug Stores
9.4.3. Online Pharmacies
10. Cystic Fibrosis Market Analysis, Insights and Forecast, 2016-2027
10.1. Key Findings / Summary
10.2. Market Analysis – By Drug Class
10.2.1. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
10.2.2. Bronchodilators
10.2.3. Mucolytic
10.2.4. Pancreatic Enzyme Supplement
10.2.5. Others
10.3. Market Analysis – By Route of Administration
10.3.1. Oral
10.3.2. Parenteral
10.4. Market Analysis – By Distribution Channel
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies & Drug Stores
10.4.3. Online Pharmacies
11. Competitive Analysis
11.1. Key Industry Developments
11.2. Global Market Share Analysis (2019)
11.3. Competition Dashboard
11.4. Comparative Analysis – Major Players
11.5. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
11.5.1. Vertex Pharmaceuticals Incorporated
11.5.1.1. Overview,
11.5.1.2. Products & services,
11.5.1.3. SWOT analysis,
11.5.1.4. Recent developments,
11.5.1.5. strategies,
11.5.1.6. financials (based on availability)
11.5.2. AbbVie Inc.
11.5.2.1. Overview,
11.5.2.2. Products & services,
11.5.2.3. SWOT analysis,
11.5.2.4. Recent developments,
11.5.2.5. strategies,
11.5.2.6. financials (based on availability)
11.5.3. Novartis AG
11.5.3.1. Overview,
11.5.3.2. Products & services,
11.5.3.3. SWOT analysis,
11.5.3.4. Recent developments,
11.5.3.5. strategies,
11.5.3.6. financials (based on availability)
11.5.4. Gilead Sciences, Inc.
11.5.4.1. Overview,
11.5.4.2. Products & services,
11.5.4.3. SWOT analysis,
11.5.4.4. Recent developments,
11.5.4.5. strategies,
11.5.4.6. financials (based on availability)
11.5.5. Mylan N.V.
11.5.5.1. Overview,
11.5.5.2. Products & services,
11.5.5.3. SWOT analysis,
11.5.5.4. Recent developments,
11.5.5.5. strategies,
11.5.5.6. financials (based on availability)
11.5.6. Pfizer Inc.
11.5.6.1. Overview,
11.5.6.2. Products & services,
11.5.6.3. SWOT analysis,
11.5.6.4. Recent developments,
11.5.6.5. strategies,
11.5.6.6. financials (based on availability)
11.5.7. Bayer AG
11.5.7.1. Overview,
11.5.7.2. Products & services,
11.5.7.3. SWOT analysis,
11.5.7.4. Recent developments,
11.5.7.5. strategies,
11.5.7.6. financials (based on availability)
11.5.8. Genentech, Inc.
11.5.8.1. Overview,
11.5.8.2. Products & services,
11.5.8.3. SWOT analysis,
11.5.8.4. Recent developments,
11.5.8.5. strategies,
11.5.8.6. financials (based on availability)
11.5.9. AstraZeneca
11.5.9.1. Overview,
11.5.9.2. Products & services,
11.5.9.3. SWOT analysis,
11.5.9.4. Recent developments,
11.5.9.5. strategies,
11.5.9.6. financials (based on availability)
11.5.10. Other Prominent Market Players
11.5.10.1. Overview,
11.5.10.2. Products & services,
11.5.10.3. SWOT analysis,
11.5.10.4. Recent developments,
11.5.10.5. strategies,
11.5.10.6. financials (based on availability)
12. Strategic Recommendations

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us